Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B

Cancer Science

Volumn 98, Issue 11, 2007, Pages 1795-1802

  Baba, Tetsuro ^a   Hanagiri, Takeshi ^a   Ichiki, Yoshinobu ^a   Kuroda, Koji ^a   Shigematsu, Yoshiki ^a   Mizukami, Makiko ^a   Sugaya, Masakazu ^a   Takenoyama, Mitsuhiro ^a   Sugio, Kenji ^a   Yasumoto, Kosei ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; HLA ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL STIMULATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FLOW CYTOMETRY; GENETIC DISORDER; GENETIC TRANSDUCTION; HAPLOTYPE; HOST RESISTANCE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LYMPH NODE; LYMPHOCYTE; MALE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TISSUE SPECIFICITY; WILD TYPE;

BETA 2-MICROGLOBULIN; CARCINOMA, LARGE CELL; CELL LINE, TUMOR; GENOTYPE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-A ANTIGENS; HLA-B ANTIGENS; HUMANS; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; T-LYMPHOCYTES, CYTOTOXIC;

EID: 34748870776     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00586.x     Document Type: Article

References (42)

1. Ichiki Y, Takenoyama M, Mizukami M et al. Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer. J Immunol 2004; 172: 4844-50.
2. So T, Takenoyama M, Mizukami M et al. Haplotype loss of HLA-class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res 2005; 65: 5945-52.
3. Nagata Y, Hanagiri T, Takenoyama M et al. Identification of the HLA-Cw*0702-restricted tumor-associated antigen recognized by a CTL clone from a lung cancer patient. Clin Cancer Res 2005; 11: 5265-72.
4. Takenoyama M, Baurain JF, Yasuda M et al. A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma. Int J Cancer 2006; 118: 1992-7.
5. Fukuyama T, Hanagiri T, Takenoyama M et al. Identification of a new cancer/germline gene, KK-LC-1, encoding an antigen recognized by autologous CTL induced on human lung adenocarcinoma. Cancer Res 2006; 66: 4922-8.
6. Coulie PG, Karanikas V, Colau D et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA 2001; 98: 10 290-5.
7. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: Moving beyond current vaccines. Nat Med 2004; 10: 909-15.
8. Dudley ME, Wunderlich JR, Yang JC et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 2346-57.
9. Speiser DE, Lienard D, Rufer N et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005; 115: 739-46.
10. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319: 675-8.
11. Bottino C, Castriconi R, Moretta L, Moretta A. Cellular ligands of activating NK receptors. Trends Immunol 2005; 26: 221-6.
12. Maio M, Altomonte M, Tatake R, Zeff RA, Ferrone S. Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA-class I antigen expression by transfection with B2m gene. J Clin Invest 1991; 8: 282-9.
13. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996; 88: 100-8.
14. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat Immunol 2002; 3: 999-1005.
15. Wang Z, Cao Y, Albino AP, Zeff RA, Houghton A, Ferrone S. Lack of HLA-class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. J Clin Invest 1993; 91: 684-92.
16. Bicknell DC, Rowan A, Bodmer WF. Beta 2-microglobulin gene mutations: A study of established colorectal cell lines and fresh tumors. Proc Natl Acad Sci USA 1994; 91: 4751-5.
17. Hicklin DJ, Wang Z, Arienti F, Rivoltini L, Parmiani G, Ferrone S. Beta2-microglobulin mutations, HLA-class I antigen loss, and tumor progression in melanoma. J Clin Invest 1998; 101: 2720-9.
18. Chang CC, Campoli M, Ferrone S. HLA class I defects in malignant lesions: What have we learned? Keio J Med 2003; 52: 220-9.
19. Chang CC, Campoli M, Restifo NP, Wang X, Ferrone S. Immune selection of hot-spot beta2-microglobulin gene mutations, HLA-A2 allo specificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. J Immunol 2005; 174: 1462-71.
20. Redondo M, Concha A, Oldiviela R et al. Expression of HLA class I and II antigens in bronchogenic carcinomas: Its relationship to cellular DNA content and clinical-pathological parameters. Cancer Res 1991; 51: 4948-54.
21. Passlick B, Izbicki JR, Simmel S et al. Expression of major histocompatibility class I and class II antigens and intercellular adhesion molecule-1 on operable non-small cell lung carcinomas: frequency and prognostic significance. Eur J Cancer 1994; 30A: 376-81.
22. Ramnath N, Tan D, Li Q et al. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? Cancer Immunol Immunother 2005; 27: 1-9.
23. Sugaya M, Takenoyama M, Osaki T et al. Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy. Chest 2000; 122: 282-8.
24. Wang Z, Arienti F, Parmiani G, Ferrone S. Induction and functional characterization of beta2-microglobulin (beta2-mu)-free HLA-class I heavy chains expressed by beta2-mu-deficient human FO-1 melanoma cells. Eur J Immunol 1998; 28: 2817-26.
25. Misawa K, Nosaka T, Morita S et al. A method to identify cDNAs based on localization of green fluorescent protein fusion products. Proc Natl Acad Sci U S A 2000; 97: 3062-6.
26. Kitamura H, Torigoe T, Honma I et al. Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus calmette-guerin immunotherapy for bladder cancer. Clin Cancer Res 2006; 12: 4641-4.
27. Takenoyama M, Yoshino I, Fujie T et al. Autologous tumor-specific cytoxic T lymphocytes in a patient with lung adenocarcinoma: implications of the shared antigens expressed in HLA-A24 lung cancer cell. Jpn J Cancer Res 1998; 89: 60-6.
28. Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 2005; 117: 248-55.
29. Watson NF, Ramage JM, Madjd Z et al. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer 2006; 118: 6-10.
30. Paschen A, Mendez RM, Jimenez P et al. Complete loss of HLA-class I antigen expression on melanoma cells: A result of successive mutational events. Int J Cancer 2003; 103: 759-67.
31. Moretta L, Bottino C, Pende D, Vitale M, Mingari MC, Moretta A. Different checkpoints in human NK activation. Trends Immunol 2004; 25: 670-6.
32. Marin R, Ruiz-Cabello F, Pedrinaci S et al. Analysis of HLA-E expression in human tumors. Immunogenetics 2003; 54: 767-75.
33. Campos-Martin Y, Gomez del Moral M, Gozalbo-Lopez B, Suela J, Martinez-Naves E. Expression of human CD1d molecules protects target cells from NK-mediated cytolysis. J Immunol 2004; 172: 7297-305.
34. Bauer S, Groh V, Wu J, Steinle A et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727-9.
35. Armeanu S, Bitzer M, Lauer UM et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005; 65: 6321-9.
36. Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A, Odum A. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 2005; 65: 11 136-45.
37. Mizuki N, Ota M, Kimura M et al. Triplet repeat polymorphism in the transmembrane region of the MICA gene: A strong association of six GCT repetitions with Behcet disease. Proc Natl Acad Sci USA 1997; 94: 1298-303.
38. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 2004; 114: 560-8.
39. Fukuyama T, Ichiki Y, Yamada S et al. Cytokine production of lung cancer cell lines: Correlation between their production and the inflammatory/ immunological responses both in vivo and in vitro. Cancer Sci 2007; 98: 1048-54.
40. Gajewski TF. Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin Cancer Res 2006; 12: 2326-30s.
41. So T, Takenoyama M, Ichiki Y et al. A different pattern of cytotoxic T lymphocyte recognition against primary and metastatic tumor cells in a patient with nonsmall cell lung carcinoma. Cancer 2005; 103: 200-8.
42. Lizee G, Radvanyi LG, Overwijk WW, Hwu P. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res 2006; 12: 4794-803.